Document Detail


Dual HER2 blockade slows metastatic breast cancer.
MedLine Citation:
PMID:  22585174     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Authors:
Eric Bender
Related Documents :
22361774 - An unusual case of non-disseminated bladder aspergillosis in a setting of transitional ...
22281894 - Squamous cell carcinoma of the penis: clinicopathologic study of 34 cases.
17323574 - Sarcomatoid renal cell carcinoma in a binturong (arctictis binturong).
22553474 - Abc1 consensus conference - a german perspective: first international consensus confere...
11719434 - Hypermethylation in human cancers of the riz1 tumor suppressor gene, a member of a hist...
18507014 - Novel link between estrogen receptor alpha and hedgehog pathway in breast cancer.
Publication Detail:
Type:  News     Date:  2011-12-15
Journal Detail:
Title:  Cancer discovery     Volume:  2     ISSN:  2159-8290     ISO Abbreviation:  Cancer Discov     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-05-15     Completed Date:  2013-01-15     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  101561693     Medline TA:  Cancer Discov     Country:  United States    
Other Details:
Languages:  eng     Pagination:  OF4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*,  enzymology,  pathology
Female
Humans
Neoplasm Metastasis
Receptor, erbB-2 / antagonists & inhibitors*,  metabolism
Taxoids / administration & dosage
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Taxoids; 114977-28-5/docetaxel; 380610-27-5/pertuzumab; EC 2.7.10.1/Receptor, erbB-2; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mathematical model could aid biomarker validation.
Next Document:  Biotech firms look for virtual success.